Adlai Nortye Group Ltd. (ANL) stock
Close on Nov 12, 2026Market cap $420.80MP/E –Yield –
Adlai Nortye Group Ltd. reported revenue of $5.00M for fiscal 2025. Free cash flow was -$33.64M. At the latest close the market valued the company at $420.80M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $420.80M
- P/E ratio
- –
- Price to sales
- 84.16
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -7.99%
Fundamentals
- Revenue
- $5.00M
- Net income
- -$35.53M
- EPS, diluted
- -$0.37
- Free cash flow
- -$33.64M
Trading
- Previous close
- $10.85
- Open
- $10.62
- Day's range
- $10.22 – $10.79
- Volume
- 130,645
- Average volume (20 days)
- 252,474
- Beta (5 years)
- 1.67
- 52-week range
- $0.88 – $17.25
- RSI (14 days)
- 45.1
- Volatility (1 year)
- 154.7%
- Relative volume
- 0.58×
- WACC
- 12.8%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANL | S&P 500 | Difference | ANL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.0% | -2.7% | −23.3 pts | ||
| 3 months | -19.6% | -1.7% | −17.9 pts | ||
| Year to date | +640.8% | +11.9% | +629.0 pts | ||
| 1 year | +553.5% | +12.0% | +541.5 pts | ||
| 3 years | +20.4% | +78.2% | −57.8 pts | +6.4% | +21.2% |
| 5 years | -26.2% | +73.2% | −99.4 pts | -5.9% | +11.6% |
| 10 years | -26.2% | +309.6% | −335.8 pts | -3.0% | +15.1% |
Six years at a glance
Fiscal years 2020 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Adlai Nortye filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Adlai Nortye
Pharmaceutical Preparations
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of innovative drug candidates. The company engages in preclinical research and clinical trials to evaluate therapeutic treatments for targeted diseases. Its operations encompass experimental pharmaceutical therapies designed to address conditions regulated by health agencies such as the United States Food and Drug Administration and the National Medical Products Administration. Its prospective end users are patients suffering from targeted illnesses.
Company profile, executives and historyAdlai Nortye stock: common questions
What is Adlai Nortye's stock price?
ANL closed at $10.52 on Nov 12, 2026, down 3.04% on the day. Over the past 52 weeks it traded between $0.88 and $17.25.
What is Adlai Nortye's market cap?
Adlai Nortye was worth $420.80M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ANL's P/E ratio?
Adlai Nortye lost money over fiscal 2025 (diluted EPS -$0.37), so it has no meaningful P/E ratio.
How much revenue does Adlai Nortye make?
Adlai Nortye reported revenue of $5.00M for fiscal 2025.
Does Adlai Nortye pay a dividend?
No. Adlai Nortye has not paid a cash dividend over the last twelve months.
How has ANL stock performed over the past year?
Including dividends, ANL returned +553.5% over the past year, against +12.0% for the S&P 500.
Who are Adlai Nortye's competitors?
Companies most similar to Adlai Nortye by business, industry and size include APLM, PTCHF, KYNB, ADAG, ENSC.
See a number that looks wrong?